Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Positive clinical data from its Phase 2 study of PL9643 in dry eye disease Pre-clinical data with melanocortins for retinal inflammation Apr 20, 2021, 07:30 ET CRANBURY, N.J., April 20, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin …